Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting

References

• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47–66. doi:10.1007/s41030-019-00109-1.
   PubMedGoogle Scholar
• Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116–124. doi:10.1136/thoraxjnl-2017-210531.
   PubMed Web of Science ®Google Scholar
• Domingo Ribas C, Sogo Sagardia A, Prina E, Sicras Mainar A, Sicras Navarro A, Engroba Teijeiro C. Prevalence, characterization and costs of severe asthma in Spain (BRAVO 1). Eur Respir J. 2020;56(suppl 64):4639.
   Google Scholar
• Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, Peche R, Manise M, Joos G. Heterogeneity of phenotypes in severe asthmatics: the Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108(12):1723–1732. doi:10.1016/j.rmed.2014.10.007.
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224. doi:10.1164/rccm.200711-1754OC.
   PubMed Web of Science ®Google Scholar
• Rial MJ, Álvarez-Puebla MJ, Arismendi E, Caballero ML, Cañas JA, Cruz MJ, González-Barcala FJ, Luna JA, Martínez-Rivera C, Mullol J, et al. Clinical and inflammatory characteristics of patients with asthma in the Spanish MEGA project cohort. Clin Transl Allergy. 2021;11(1):e12001.
   PubMed Web of Science ®Google Scholar
• Azim A, Newell C, Barber C, Harvey M, Knight D, Freeman A, Fong WCG, Dennison P, Haitchi HM, Djukanovic R, et al. Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts. Clin Exp Allergy. 2021;51(6):811–820. doi:10.1111/cea.13841.
   PubMed Web of Science ®Google Scholar
• Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, Christoff GC, Cosio BG, FitzGerald JM, Heffler E, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814–830. doi:10.1016/j.chest.2021.04.013.
   PubMed Web of Science ®Google Scholar
• Nucala (Mepolizumab) [FichaTécnica]. European Medicines Agency; Published December 2015. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR__Product_Information/human/003860/WC500198037.pdf [accessed 30 January 2019].
   Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomized, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X.
   PubMed Web of Science ®Google Scholar
• Domingo Ribas C, Carrillo Díaz T, Blanco Aparicio M, Martínez Moragón E, Banas Conejero D, Sánchez Herrero MG, Muñoz M, Cabrerizo H, Valero A, Arismendi E, REDES Study Group, et al. Correction to: REal world effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study. Drugs. 2021;81(16):1949–1951. doi:10.1007/s40265-021-01622-x.
   PubMed Web of Science ®Google Scholar
• Enríquez-Rodríguez AI, Hermida Valverde T, Romero Álvarez P, López-González FJ, Gullón Blanco JA, Expósito Villegas AR, Escobar Fernández MJ, Beristáin Urquiza AM, Alonso Fernández MÁ, Gutiérrez Rodríguez M, et al. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study. J Asthma. 2022;59(5):1005–1011. doi:10.1080/02770903.2021.1897835.
   PubMed Web of Science ®Google Scholar
• Pilette C, Canonica GW, Chaudhuri R, Chupp G, Lee FE, Lee JK, Almonacid C, Welte T, Alfonso-Cristancho R, Jakes RW, et al. REALITI-A study: Real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10(10):2646–2656. 00629 doi:10.1016/j.jaip.2022.05.042.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, d’Ancona G, Elstad M, Green L, Fernandes M, Thomson L, Roxas C, Dhariwal J, Nanzer AM, Kent BD, et al. Real-world effectiveness and the characteristics of a “Super-Responder” to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500. doi:10.1016/j.chest.2020.03.042.
   PubMed Web of Science ®Google Scholar
• Martinez-Moragon E. Cost-effectiveness of biologic therapies in asthma in Spain. Arch Bronchopneumol. 2023:S0300-2896(23)00165-5.
   Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–225. doi:10.1016/j.anai.2016.10.028.
   PubMed Web of Science ®Google Scholar
• Tan LI, Tan WHG, Aziz MIA, Koh MS, Tay TR, Pearce F, Ng K. Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore. J Asthma. 2022;59(1):189–199. doi:10.1080/02770903.2020.1837158.
   PubMed Web of Science ®Google Scholar
• González-Barcala FJ, Muñoz-Gall X, Mariscal E, García A, Yang S, van de Wetering G, Izquierdo-Alonso JL. Cost-effectiveness analysis of anti-IL-5 therapies of severe eosinophilic asthma in Spain. J Med Econ. 2021;24(1):874–882. doi:10.1080/13696998.2021.1941065.
   PubMed Web of Science ®Google Scholar
• Plaza V, Alobid I, Alvarez C, Blanco M, Ferreira J, García G, Gómez-Outes A, Gómez F, Hidalgo A, Korta J, et al. Spanish Asthma Management Guidelines (GEMA) VERSION 5.1. Highlights and controversies. Arch Bronconeumol. 2022;58(2):150–158. doi:10.1016/j.arbres.2021.05.010.
   PubMed Web of Science ®Google Scholar
• Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, Carpagnano E, Contoli M, Corsico A, Del Giacco S, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29(156):190137. doi:10.1183/16000617.0137-2019.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the mini asthma quality of life questionnaire. Eur Respir J. 1999;14(1):32–38. doi:10.1034/j.1399-3003.1999.14a08.x.
   PubMed Web of Science ®Google Scholar
• Burn J, Sims AJ, Patrick H, Heaney LG, Niven RM. Efficacy and safety of bronchial thermoplasty in clinical practice: a prospective, longitudinal, cohort study using evidence from the UK Severe Asthma Registry. BMJ Open. 2019;9(6):e026742. doi:10.1136/bmjopen-2018-026742.
   PubMed Web of Science ®Google Scholar
• Gisbert R, Brosa M. Spanish health costs and cost-effectiveness ratios database: eSalud [Internet]. Barcelona: Oblikue Consulting, S.L.; 2007. http://www.oblikue.com/bddcostes/ [latest update: 2018; accessed 15 February 2022].
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF). Base de datos de medicamentos BotPlus 2.0; 2020. https://botplusweb.portalfarma.com/.
   Google Scholar
• Instituto Nacional de Estadística (INE). Nivel y condiciones de vida (IPC). https://www.ine.es/dyngs/INEbase/categoria.htm?c=Estadistica_P&cid=1254735976604 [accessed 8 March 2022].
   Google Scholar
• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.
   PubMedGoogle Scholar
• Louis G, Pétré B, Schleich F, Zahrei HN, Donneau AF, Henket M, Paulus V, Guissard F, Guillaume M, Louis R. Predictors of change in asthma-related quality of life: a longitudinal real-life study in adult asthmatics. Qual Life Res. 2023;32(5):1507–1520. doi:10.1007/s11136-022-03339-0.
   PubMed Web of Science ®Google Scholar
• Israel E, Canonica GW, Brusselle G, Yang S, Howarth PH, Martin AL, Koufopoulou M, Smith SG, Alfonso-Cristancho R. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. J Asthma. 2022;59(11):2201–2217.
   Google Scholar
• Almonacid Sánchez C, Melero Moreno C, Quirce Gancedo S, Sánchez-Herrero MG, Álvarez Gutiérrez FJ, Bañas Conejero D, Cardona V, Soriano JB. PAGE Study: summary of a study protocol to estimate the prevalence of severe asthma in Spain using big data methods. J Investig Allergol Clin Immunol. 2021;31(4):308–315. doi:10.18176/jiaci.0483.
   PubMed Web of Science ®Google Scholar
• Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy. 2022;52(5):616–627. doi:10.1111/cea.14112.
   PubMed Web of Science ®Google Scholar
• Carta A, Conversano C. On the use of Markov models in pharmacoeconomics: pros and cons and implications for policy makers. Front Public Health. 2020;8:569500. doi:10.3389/fpubh.2020.569500.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Campillo-Artero C, Puig-Junoy J, Pinto-Prades JL, Dilla T, Rubio-Terrés C, Ortún V. What is an efficient health intervention in Spain in 2020? Gac Sanit. 2020;34(2):189–193. doi:10.1016/j.gaceta.2019.06.007.
   PubMed Web of Science ®Google Scholar
• Melero Moreno C, Quirce S, Huerta A, Uría E, Cuesta M. Economic impact of severe asthma in Spain: multicentre observational longitudinal study. J Asthma. 2019;56(8):861–871. doi:10.1080/02770903.2018.1499035.
   PubMed Web of Science ®Google Scholar
• Pérez de Llano LA, Villoro R, Merino M, Gómez Neira MdC, Muñiz C, Hidalgo Á. Cost effectiveness of outpatient asthma clinics. Arch Bronconeumol. 2016;52(4):196–203. doi:10.1016/j.arbres.2015.09.009.
   PubMed Web of Science ®Google Scholar
• Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;13:77–87. doi:10.2147/JAA.S236609.
   PubMed Web of Science ®Google Scholar
• Andersson M, Janson C, Kristensen T, Szende A, Golam S. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden. J Med Econ. 2020;23(8):877–884. doi:10.1080/13696998.2020.1760285.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost effectiveness of pharmacological treatments for asthma: a systematic review. Pharmacoeconomics. 2018;36(10):1165–1200. doi:10.1007/s40273-018-0668-8.
   PubMed Web of Science ®Google Scholar
• Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):121–131. doi:10.1080/14737167.2017.1298444.
   PubMed Web of Science ®Google Scholar
• García-Lorenzo B, Vallejo-Torres L, Trujillo-Martín MM, Perestelo-Pérez L, Valcárcel-Nazco C, Serrano Aguilar P. Evaluación económica busca umbral para apoyar la toma de decisiones [Economic evaluation seeks threshold to support decision-making]. Rev Esp Salud Publica. 2015;89(6):537–544. doi:10.4321/S1135-57272015000600002.
   PubMed Web of Science ®Google Scholar
• Domínguez-Ortega J, Delgado Romero J, Muñoz Gall X, Marco A, Blanco-Aparicio M. Use of systemic glucocorticoids for the treatment of severe asthma: Spanish multidisciplinary consensus. Open Respir Arch. 2022;4(4):100202. doi:10.1016/j.opresp.2022.100202.
   PubMedGoogle Scholar
• Domingo C, Sogo A, Casado E, Martínez-Moragón E, Blanco-Aparicio M, Carrillo T, Bañas-Conejero D, Sánchez-Herrero MG. Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma. Front Pharmacol. 2023;14:1183156. doi:10.3389/fphar.2023.1183156.
   PubMed Web of Science ®Google Scholar